Human interferon α1b Inhalation not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive Human interferon α1b Inhalation Solution”In the company’s words, NCT06363370 on ClinicalTrials.gov
- Tested for
- Respiratory Syncytial Virus Infections
- Main trialPhase 3
- “To evaluate the efficacy and safety of interferon α1b (GB05) in the treatment of children under 2 years of age with respiratory syncytial virus infection.”In the company’s words, NCT06363370 on ClinicalTrials.gov
Other drugs for Respiratory Syncytial Virus Infections
- RSVPreF3 OA vaccineGSK · Phase 3
- ABRYSVOPfizer · Phase 3
- ZiresovirShanghai Ark Biopharmaceutical Co., Ltd. · Phase 2/3
- S-337395Shionogi · Phase 2
- ZelicapavirEnanta Pharmaceuticals, Inc · Phase 2
- Investigational hMPV vaccineSanofi · Phase 1/2
Coming up1
- 30 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Jun 2027 | Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026